Q-omics provides the consensus-scored SORT1 profile across patient tissues and cancer cell-line models. SORT1 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SORT1 is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, SORT1 protein abundance shows 33,517 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, and GBM as cancer lineages where SORT1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SORT1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SORT1 survival associations across molecular data types. SORT1 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (5) and mass-spec protein abundance (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SORT1 RNA expression–survival associations across cancer types. High SORT1 expression shows unfavorable associations in MESO, LIHC, LGG and LAML, but favorable associations in KIRC and COAD. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SORT1 RNA expression.
This table summarizes SORT1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 10. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for SORT1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SORT1 shows lower tumor expression in KIRC, HNSC, KICH, THCA and LUSC and higher tumor expression in LIHC. The KIRC box plot shows higher SORT1 RNA expression in normal versus tumor tissue (log2 FC = −1.493, t-test p < 0.001).
This table shows molecular features associated with SORT1 in patient tissues and cancer cell lines. In patient samples, SORT1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, SORT1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Leukemia.
